Sunshine Biopharma Inc. (SBFM) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Sunshine Biopharma Inc. operates primarily through two Canadian subsidiaries: Nora Pharma Inc., which markets 76 generic prescription drugs in Canada, and Sunshine Biopharma Canada Inc., which develops over-the-counter (OTC) supplements. The company is also developing proprietary drugs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The registrant is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | Value |
|---|---|
| Revenue | $27,728,750 |
| Net Loss | $(3,834,425) |
| Loss Per Share (Basic) | $(0.98) |
| Gross Profit | $9,226,832 (33.3% Margin) |
| Operating Cash Flow | $(3,715,067) |
| Cash and Equivalents (End of Period) | $9,306,438 |
| Total Assets | $31,487,379 |
| Total Liabilities | $7,288,023 |
| Shareholders' Equity | $24,199,356 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.7% to $27.7 million for the nine months ended Sept 30, 2025, compared to $25.3 million in the prior year period, driven by enhanced marketing efforts.
- Margin Improvement: Gross margin improved to 33.3% (from 30.0% in 2024) due to better procurement costs for finished products.
- Intangible Asset Impairment: A significant non-cash charge of $1,616,459 was recorded for the impairment of intangible assets, as certain product licenses were deemed non-commercializable. This contributed to a higher operating loss compared to the prior year.
- Financing Activity: The company raised $1.83 million in net proceeds from a registered direct offering in April 2025 and $2.20 million from warrant exercises. This contrasts with the prior year, which saw larger financing proceeds ($8.5 million) but also significant treasury stock repurchases ($3.1 million).
- Inventory Build: Inventory increased by approximately $2.8 million to $14.1 million, reflecting a buildup of finished goods.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($9.3 million) combined with operating cash flow will fund operations for the next 24 months. However, no committed sources of capital exist, and future fundraising may be necessary for R&D and clinical trials.
- Strategic Pivot: The company aims to reduce the cost of goods sold from ~67% to ~60% to reach breakeven. Management previously announced a plan to invest $5 million in Bitcoin but abandoned this plan due to market volatility.
- Legal Contingency: Following the termination of Mr. Malek Chamoun (former President of Nora Pharma) in April 2025, the company received a demand letter seeking approximately $5.3 million USD (CAD $7.3 million). The company disputes the claim as unfounded and has made no accrual for this liability.
- Regulatory Risk: The company's generic drug pricing is heavily dependent on Canadian government reimbursement policies and negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA).
Investor Verification Checklist
- Disputed Liability: Verify the status of the $5.3 million claim from the terminated subsidiary president and potential legal costs.
- Impairment Validity: Review the specific product licenses written off ($1.6M) to assess if this indicates broader commercialization issues.
- Inventory Turnover: Monitor the $14.1 million inventory balance against sales velocity to ensure no further obsolescence charges are needed.
- Capital Needs: Assess the runway of $9.3 million against the stated goal of reaching breakeven and the potential need for dilutive financing.
- Warrant Overhang: Note the existence of ~15.6 million Series B warrants outstanding with an exercise price of $2.07, which could impact future share count.